Physician profile
Michael James Johnson
NPI 1841391471
$12,937.48
in general payments reported to CMS, 2019-2025
24 companies · $3,535 in 2025
The $3,535 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,875 · 2020: $229 · 2021: $1,329 · 2022: $2,105 · 2023: $2,052 · 2024: $1,814 · 2025: $3,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,651 · Consulting Fee: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,651.32 |
| Consulting Fee | $749.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $4,735.66 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,892.38 | 2019-2025 | Precision 1, Total30, Precision7 |
| Bausch & Lomb Americas INC. | $1,819.09 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $796.92 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Onefit Contact Lens |
| Oyster Point Pharma, INC. | $628.37 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $564.92 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $433.56 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $381.93 | 2019-2021 | |
| Dompe US, INC. | $299.36 | 2021-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $262.59 | 2019-2022 | |
| Optos, INC. | $207.90 | 2019 | |
| Glaukos Corporation | $179.27 | 2025 | Radius Xr |
| Abb Con-Cise Optical Group LLC | $177.85 | 2023-2025 | Spectacle Lenses, Contact Lens |
| Maculogix, INC. | $128.87 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $113.80 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $90.30 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $42.00 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $40.92 | 2021 | |
| Allergan, INC. | $40.49 | 2021-2022 | |
| Lumenis Be INC | $28.70 | 2024 | Optilight |
| Heidelberg Engineering, INC. | $24.78 | 2022 | |
| Shire North American Group INC | $19.12 | 2019 | |
| Topcon Healthcare, INC. | $16.62 | 2025 | |
| Notal Vision, INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.